In October, high-profile U.K. fund manager Neil Woodford advocated for a four-way break-up of GlaxoSmithKline, a company he said could unlock “significant shareholder value” by splitting apart. And he hasn’t quit championing that idea.
As Woodford told the BBC Friday, GSK is so complicated that it runs itself “like four FTSE 100 companies bolted together”–and, on top of that, the pharma giant doesn’t “do a particularly good job of managing all of the constituent parts.”
Instead, he said, he’d like to see the company “focus on certain activities in the portfolio and do them better than they have done in the past, demerge the bits they haven’t managed particularly well and let other people who specialize in those activities run those businesses.”
It’s basically Big Pharma’s slim-down mantra to a tee. Over the last few years, companies have been hiving off or trading away non-core assets to home in on what they do best; Glaxo itself was part of a multi-billion-dollar asset swap last year with Novartis that sent its oncology meds to Switzerland, bolstered its position in the vaccines market and set up an industry-leading consumer health joint venture.
But the way Woodford sees it, that’s not enough. The sum of Glaxo’s parts is still worth more than its current share price, he told the news service.
If it’s a large-scale restructuring he wants, though, he’ll have to take it up with CEO Andrew Witty, who made it clear on the company’s Q3 conference call that the drugmaker had thoroughly considered–and decided against–any divestment moves. Glaxo has already weighed an established products sale, he said, but “that just wasn’t a good economic transaction to do.”
And as far as a spinoff of surging HIV drugs business ViiV Healthcare–it’s not happening, the CEO said, echoing the decision GSK made last May after weighing a divestment for months.
“We took the decision not to separate it because we believed we were the best owners,” he said. “… And I think we’ve been vindicated since.”
By Carly Helfand
Source: Fierce Pharma
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.
